Home  »  Business   »  Short Term Estimates And Forecasts For Abbott Labo...

Short Term Estimates And Forecasts For Abbott Laboratories (ABT)

Abbott Laboratories (NYSE:ABT) has a beta value of 0.67 and has seen 4.66 million shares traded in the last trading session. The company, currently valued at $194.43B, closed the last trade at $112.53 per share which meant it lost -$1.48 on the day or -1.30% during that session. The ABT stock price is -16.35% off its 52-week high price of $130.93 and 17.13% above the 52-week low of $93.25. If we look at the company’s 10-day average daily trading volume, we find that it stood at 5.56 million shares traded. The 3-month trading volume is 5.08 million shares.

Abbott Laboratories (NYSE:ABT) trade information

Sporting -1.30% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on Tuesday, 01/24/23 when the ABT stock price touched $112.53 or saw a rise of 1.89%. Year-to-date, Abbott Laboratories shares have moved 2.50%, while the 5-day performance has seen it change -0.76%. Over the past 30 days, the shares of Abbott Laboratories (NYSE:ABT) have changed 4.06%. Short interest in the company has seen 16.68 million shares shorted with days to cover at 3.51.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.


Abbott Laboratories (ABT) estimates and forecasts

Figures show that Abbott Laboratories shares have underperformed across the wider relevant industry. The company’s shares have gained 3.71% over the past 6 months, with this year growth rate of 0.00%, compared to 2.00% for the industry. Revenue growth from the last financial year stood is estimated to be 0.30%.

16 analysts offering their estimates for the company have set an average revenue estimate of $9.64 billion for the current quarter. 10 have an estimated revenue figure of $9.39 billion for the next quarter concluding in Mar 2023. Year-ago sales stood $11.47 billion and $11.89 billion respectively for this quarter and the next, and analysts expect sales will shrink by -15.90% for the current quarter and -21.00% for the next.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 40.70% over the past 5 years. Earnings growth for 2023 is a modest 57.00% while over the next 5 years, the company’s earnings are expected to increase by 8.30%.

ABT Dividends

Abbott Laboratories is expected to release its next earnings report on January 25 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue. The forward dividend is 2.04 at a share yield of 1.81%. The company’s dividend yield has gone up over the past 12 months.

Abbott Laboratories (NYSE:ABT)’s Major holders

Insiders own 0.73% of the company shares, while shares held by institutions stand at 76.16% with a share float percentage of 76.72%. Investors are also buoyed by the number of investors in a company, with Abbott Laboratories having a total of 3,308 institutions that hold shares in the company. The top two institutional holders are Vanguard Group, Inc. (The) with over 154.56 million shares worth more than $17.39 billion. As of Sep 29, 2022, Vanguard Group, Inc. (The) held 8.86% of shares outstanding.

The other major institutional holder is Blackrock Inc., with the holding of over 133.34 million shares as of Sep 29, 2022. The firm’s total holdings are worth over $15.0 billion and represent 7.65% of shares outstanding.

Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Vanguard 500 Index Fund. As of Sep 29, 2022, the former fund manager holds about 3.00% shares in the company for having 52.25 million shares of worth $5.88 billion while later fund manager owns 39.7 million shares of worth $4.47 billion as of Sep 29, 2022, which makes it owner of about 2.28% of company’s outstanding stock.

Leave a Comment

Your email address will not be published. Required fields are marked *

On Key

Related Posts

5 Lithium Stocks with High Future Potential

Demand for lithium is expected to increase 8-fold by 2030. The world's largest automakers are racing to go green as the global EV boom continues.


We have collated a list of top five lithium stocks which are well positioned to benefit from the 2023 lithium boom because of their focus on multiple high-potential lithium projects.

100% free. stop anytime no spam